G.d. Searle & Company

Pfizer Corporation

G.d. Searle LLC

James E Truelove

Rajeev D Gokhale

Michel R Franz

Tugrul T Kararli

Aziz Karim

Martin John Griffin

Anthony J Hlinak

Michel R Jans

James C Stolzenbach

Danchen Gao

Stanley C Penzotti, Jr

Ajit K Roy

David Otto

Margaret B Vaughn

Ahmad M Mazhary

Kamlesh B Shah

Leo K Mathur

Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising particulate celecoxib in an amount of about 10 mg to about 1000 mg in intimate mixture with one or more pharmaceutically acceptable excipients. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders.

Celecoxib compositions

Oral pharmaceutical formulation which improves the bioavailability of pharmaceuticals which are substantially water and oil insoluble is disclosed. In addition to the pharmaceutical, the formulation includes an emulsifier, an oil and an solubilizer. Alternatively, the formulation includes an aqueous solution of solubilizer.

Self-emulsifying drug delivery system

The present invention provides for stabilization of misoprostol in solid dispersions using amorphous excipients or excipients which have been converted to an amorphous state such as hydroxypropyl cellulose, methyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, cellulose acetate phthalate, cellulose acetate butyrate, hydroxyethyl cellulose, ethyl cellulose, polyvinyl alcohol, polyethylene glycol, starch, polypropylene, dextrans, dextrins, hydroxypropyl .beta.-cyclodextrin chitosan, co-(lactic/glycolic)copolymers, poly(orthoester), polyvinyl chloride, polyvinyl acetate, ethylene vinyl acetate, lectins, carbopols, silicon elastomers, cyclodextrins, polyacrylic polymers, maltodextrins, lactose, fructose, inositol, trehalose, maltose, and raffinose, (and other mono-, di- and tri- saccharides) and .alpha.-, .beta.- and .gamma.-cyclodextrins, and more preferably the excipients which are used are dextran, maltodextrin, hydroxypropyl .beta.-cyclodextrin and maltose.

Stabilized dispersions of misoprostol

A stabilized pharmaceutical composition which is an admixture of an NSAID selected from diclofenac and piroxicam, a prostaglandin and hydroxypropyl methylcellulose for maintaining the prostaglandin in a therapeutically effective amount without negatively affecting the therapeutic activity of the NSAID.

Stabilized pharmaceutical admixture composition

Growing community of inventors

Libertyville, IL, United States of America

James E Truelove